Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status.
Yoh Yamaguchi; Tatsuya Yoshida; Ryoko Inaba Higashiyama; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Anticancer research, Feb. 2026

Genetic Characteristics of Disease Flare After Lenvatinib Discontinuation in Patients With Thymic Carcinoma: A Brief Report.
Tomoaki Nakamura; Tatsuya Yoshida; Ken Masuda; Jun Sato; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
JTO clinical and research reports, Dec. 2025

Exacerbation of cancer-associated retinopathy with anti-recoverin antibodies during atezolizumab treatment for extensive-stage small cell lung cancer: A case report.
Tomoaki Nakamura; Tatsuya Yoshida; Kohdai Kitamoto; Ken Masuda; Yi-Ning Chen; Yasushi Goto
Respiratory investigation, Sep. 2025

Effects of Sarcopenia on the Outcomes and Safety of Chemoradiotherapy Followed by Durvalumab for the Treatment of Patients With Locally Advanced Non-Small Cell Lung Cancer.
Kentaro Tamura; Hidehito Horinouchi; Mototaka Miyake; Ken Masuda; Yuki Shinno; Yusuke Okuma; Tatsuya Yoshida; Noboru Yamamoto; Yasushi Goto
Thoracic cancer, Aug. 2025

Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure.
Yoh Yamaguchi; Yuki Shinno; Ken Masuda; Ryo Ariyasu; Kaname Nosaki; Taiki Hakozaki; Takaaki Tokito; Shogo Nomura; Makoto Nishio; Koichi Goto; Yukio Hosomi; Koichi Azuma; Yuichiro Ohe
Current problems in cancer, Jun. 2025

Successful Treatment of HER2 V659E Mutation‐Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report
Mariko Nishihara; Yuki Shinno; Yoshihiro Masui; Ken Masuda; Yuji Matsumoto; Yusuke Okuma; Tatsuya Yoshida; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Thoracic Cancer, Jun. 2025

Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma.
Masahiro Torasawa; Tatsuya Yoshida; Kouya Shiraishi; Shigehiro Yagishita; Hanako Ono; Yuji Uehara; Jun Miyakoshi; Akiko Tateishi; Yukiko Shimoda Igawa; Ryoko Inaba Higashiyama; Akifumi Mochizuki; Ken Masuda; Yuji Matsumoto; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Ryuji Hamamoto; Noboru Yamamoto; Shun-Ichi Watanabe; Yasushi Yatabe; Kazuhisa Takahashi; Takashi Kohno; Yuichiro Ohe
Lung cancer (Amsterdam, Netherlands), Apr. 2025

Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapies
Hironori Satoh; Yusuke Okuma; Yuki Shinno; Ken Masuda; Yuji Matsumoto; Tatsuya Yoshida; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Lung Cancer, Apr. 2025

A series of natural language processing for predicting tumor response evaluation and survival curve from electronic health records.
Toshiki Takeuchi; Hidehito Horinouchi; Ken Takasawa; Masami Mukai; Ken Masuda; Yuki Shinno; Yusuke Okuma; Tatsuya Yoshida; Yasushi Goto; Noboru Yamamoto; Yuichiro Ohe; Mototaka Miyake; Hirokazu Watanabe; Masahiko Kusumoto; Takashi Aoki; Kunihiro Nishimura; Ryuji Hamamoto
BMC medical informatics and decision making, 17 Feb. 2025

Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes
Ken Masuda; Tatsuya Yoshida; Noriko Motoi; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Shun‐ichi Watanabe; Tomoaki Hoshino; Yasushi Yatabe; Yuichiro Ohe
Thoracic Cancer, Jan. 2025

The remarkable antitumor efficacy of corticosteroid treatment in patients with refractory thymomas.
Tomohiro Tanaka; Yasushi Goto; Ken Masuda; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Tatsuya Yoshida; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Respiratory investigation, Sep. 2024

Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
Jun Miyakoshi; Tatsuya Yoshida; Jumpei Kashima; Masayuki Shirasawa; Masahiro Torasawa; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Kouya Shiraishi; Takashi Kohno; Noboru Yamamoto; Yasushi Yatabe; Takuji Suzuki; Yuichiro Ohe
Lung cancer (Amsterdam, Netherlands), May 2024

Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
Kentaro Tamura; Yusuke Okuma; Shogo Nomura; Akito Fukuda; Ken Masuda; Yuji Matsumoto; Yuki Shinno; Tatsuya Yoshida; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Journal of cancer research and clinical oncology, 26 Apr. 2024

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations.
Yuki Takeyasu; Tatsuya Yoshida; Ken Masuda; Yuji Matsumoto; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
JTO clinical and research reports, Feb. 2024

Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Masayuki Shirasawa; Tatsuya Yoshida; Kouya Shiraishi; Naoko Goto; Shigehiro Yagishita; Tatsuya Imabayashi; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Masaya Yotsukura; Yukihiro Yoshida; Kazuo Nakagawa; Katsuhiko Naoki; Takaaki Tsuchida; Ryuji Hamamoto; Noboru Yamamoto; Noriko Motoi; Takashi Kohno; Shun-Ichi Watanabe; Yuichiro Ohe
British journal of cancer, Dec. 2023

Correction: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Masayuki Shirasawa; Tatsuya Yoshida; Kouya Shiraishi; Naoko Goto; Shigehiro Yagishita; Tatsuya Imabayashi; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Masaya Yotsukura; Yukihiro Yoshida; Kazuo Nakagawa; Katsuhiko Naoki; Takaaki Tsuchida; Ryuji Hamamoto; Noboru Yamamoto; Noriko Motoi; Takashi Kohno; Shun-Ichi Watanabe; Yuichiro Ohe
British journal of cancer, Dec. 2023

Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy.
Tomohiro Tanaka; Yasushi Goto; Masafumi Horie; Ken Masuda; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Tatsuya Yoshida; Hidehito Horinouchi; Noriko Motoi; Yasushi Yatabe; Shunichi Watanabe; Noboru Yamamoto; Yuichiro Ohe
Cancers, 08 Aug. 2023

Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.
Yukiko Shimoda; Tatsuya Yoshida; Jun Miyakoshi; Masahiro Torasawa; Akiko Tateishi; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Cancer immunology, immunotherapy : CII, Aug. 2023

Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective study.
Tomoaki Nakamura; Tatsuya Yoshida; Yuki Takeyasu; Ken Masuda; Yuki Sinno; Yuji Matsumoto; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Translational lung cancer research, 31 Jul. 2023

Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma.
Kanako Nishimatsu; Yuji Matsumoto; Jumpei Kashima; Tatsuya Imabayashi; Keigo Uchimura; Hideaki Furuse; Ken Masuda; Yuki Shinno; Yusuke Okuma; Tatsuya Yoshida; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Takaaki Tsuchida; Yuichiro Ohe; Yasushi Yatabe
Translational lung cancer research, 30 Jun. 2023

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Masahiro Torasawa; Tatsuya Yoshida; Yuki Takeyasu; Yukiko Shimoda; Akiko Tateishi; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Kazuhisa Takahashi; Yuichiro Ohe
Cancer medicine, Jun. 2023

Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
Masayuki Shirasawa; Tatsuya Yoshida; Kouya Shiraishi; Ayako Takigami; Daisuke Takayanagi; Tatsuya Imabayashi; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Masaya Yotsukura; Yukihiro Yoshida; Kazuo Nakagawa; Takaaki Tsuchida; Ryuji Hamamoto; Noboru Yamamoto; Noriko Motoi; Takashi Kohno; Shun-Ichi Watanabe; Yuichiro Ohe
Lung cancer (Amsterdam, Netherlands), May 2023

Real-world Data on the Incidence of Coronavirus Disease (COVID-19) in Patients With Advanced Thoracic Cancer During the Early Phase of the Pandemic in Japan.
Akito Fukuda; Tatsuya Yoshida; Shigehiro Yagishita; Mika Shiotsuka; Osamu Kobayashi; Satoshi Iwata; Hitomi Umeguchi; Masatoshi Yanagida; Yasuhiro Irino; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Akinobu Hamada; Noboru Yamamoto; Yuichiro Ohe
Anticancer research, Feb. 2023

Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies.
Tomohiro Tanaka; Tatsuya Yoshida; Ken Masuda; Yuki Takeyasu; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Respiratory investigation, Jan. 2023

Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series study.
Yoshitaka Seki; Tatsuya Yoshida; Takashi Kohno; Ken Masuda; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Kazuyoshi Kuwano; Yuichiro Ohe
Respiratory investigation, Nov. 2022

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients.
Mayu Ohuchi; Shigehiro Yagishita; Hitomi Jo; Kazumasa Akagi; Ryoko Inaba Higashiyama; Ken Masuda; Yuki Shinno; Yusuke Okuma; Tatsuya Yoshida; Yasushi Goto; Hidehito Horinouchi; Yoshinori Makino; Noboru Yamamoto; Yuichiro Ohe; Akinobu Hamada
Lung cancer (Amsterdam, Netherlands), Nov. 2022

Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
Ryoko Inaba Higashiyama; Tatsuya Yoshida; Shigehiro Yagishita; Mayu Ohuchi; Naomi Sakiyama; Masahiro Torasawa; Masayuki Shirasawa; Ken Masuda; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Akinobu Hamada; Yuichiro Ohe
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Oct. 2022

Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients.
Yukiko Shimoda; Ryota Shibaki; Tatsuya Yoshida; Shuji Murakami; Masayuki Shirasawa; Masahiro Torasawa; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe; Noriko Motoi
Clinical lung cancer, Sep. 2022

Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Yuki Shinno; Akihiko Yoshida; Ken Masuda; Yuji Matsumoto; Yusuke Okuma; Tastuya Yoshida; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yasushi Yatabe; Yuichiro Ohe
Clinical lung cancer, Jul. 2022

Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis.
Masahiro Torasawa; Tatsuya Yoshida; Shigehiro Yagishita; Yukiko Shimoda; Masayuki Shirasawa; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Kazuhisa Takahashi; Yuichiro Ohe
Lung cancer (Amsterdam, Netherlands), May 2022

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib.
Yuki Takeyasu; Tatsuya Yoshida; Ken Masuda; Yuji Matsumoto; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
JTO clinical and research reports, May 2022

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression.
Hiroshi Takumida; Hidehito Horinouchi; Ken Masuda; Yuki Shinno; Yusuke Okuma; Tatsuya Yoshida; Yasushi Goto; Noboru Yamamoto; Yuichiro Ohe
Cancer immunology, immunotherapy : CII, Mar. 2022

Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancer.
Akiko Tateishi; Hidehito Horinouchi; Tatsuya Yoshida; Ken Masuda; Hitomi Jo; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Noboru Yamamoto; Yuichiro Ohe
Respiratory investigation, Mar. 2022

Effect of paracentesis on the survival of patients with terminal cancer and ascites: A propensity score-weighted analysis of the East-Asian collaborative cross-cultural Study to Elucidate the Dying process
Ken Masuda; Hiroto Ishiki; Naosuke Yokomichi; Takuhiro Yamaguchi; Tetsuya Ito; Hana Takatsu; Koji Amano; Shuji Hiramoto; Toshihiro Yamauchi; Takashi Kawaguchi; Masanori Mori; Yosuke Matsuda; Takashi Yamaguchi
04 Feb. 2022

Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.
Masayuki Shirasawa; Tatsuya Yoshida; Tatsuya Imabayashi; Kae Okuma; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Takaaki Tsuchida; Noboru Yamamoto; Yuko Nakayama; Shun-Ichi Watanabe; Noriko Motoi; Yuichiro Ohe
European journal of cancer (Oxford, England : 1990), Feb. 2022

Performance of Japanese patients in registrational studies.
Yasushi Goto; Sayaka Arakawa; Masayuki Shirasawa; Ryoko Higashiyama; Keisuke Baba; Ken Masuda; Yuki Shinno; Yuji Matsumoto; Yusuke Okuma; Tatsuya Yoshida; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Japanese journal of clinical oncology, 03 Jan. 2022

Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005).
Jiyun Lee; Aaron C Tan; Siqin Zhou; Shinkyo Yoon; Siyang Liu; Ken Masuda; Hidetoshi Hayashi; Ullas Batra; Dong-Wan Kim; Yasushi Goto; Sze Huey Tan; Yi-Long Wu; Dae Ho Lee; Daniel S W Tan; Myung-Ju Ahn
JTO clinical and research reports, Jan. 2022

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Masayuki Shirasawa; Tatsuya Yoshida; Yukiko Shimoda; Daisuke Takayanagi; Kouya Shiraishi; Takashi Kubo; Sachiyo Mitani; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Hitoshi Ichikawa; Takashi Kohno; Noboru Yamamoto; Shingo Matsumoto; Koichi Goto; Shun-Ichi Watanabe; Yuichiro Ohe; Noriko Motoi
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Dec. 2021

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions.
Chie Morita; Tatsuya Yoshida; Masayuki Shirasawa; Ken Masuda; Yuji Matsumoto; Yuki Shinno; Shigehiro Yagishita; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Noboru Yamamoto; Noriko Motoi; Yasushi Yatabe; Yuichiro Ohe
Scientific reports, 21 Sep. 2021

Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
Masayuki Shirasawa; Tatsuya Yoshida; Daisuke Takayanagi; Kouya Shiraishi; Shigehiro Yagishita; Katsutoshi Sekine; Shintaro Kanda; Yuji Matsumoto; Ken Masuda; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Hidehito Horinouchi; Akinobu Hamada; Takashi Kohno; Noboru Yamamoto; Shun-Ichi Watanabe; Yuichiro Ohe; Noriko Motoi
Clinical lung cancer, Jul. 2021

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Ken Masuda; Hidehito Horinouchi; Midori Tanaka; Ryoko Higashiyama; Yuki Shinno; Jun Sato; Yuji Matsumoto; Yusuke Okuma; Tatsuya Yoshida; Yasushi Goto; Noboru Yamamoto; Yuichiro Ohe
Journal of cancer research and clinical oncology, Jan. 2021

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Ken Masuda; Hirokazu Shoji; Kengo Nagashima; Shun Yamamoto; Masashi Ishikawa; Hiroshi Imazeki; Masahiko Aoki; Takahiro Miyamoto; Hidekazu Hirano; Yoshitaka Honma; Satoru Iwasa; Natsuko Okita; Atsuo Takashima; Ken Kato; Narikazu Boku
BMC cancer, 21 Oct. 2019

Questions Regarding the Randomized Phase II Trial of Defactinib as Maintenance Therapy in Malignant Pleural Mesothelioma.
Ken Masuda; Hiroto Ishiki; Shunsuke Oyamada; Masaki Shimizu; Daisuke Kiuchi; Eriko Satomi
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 Sep. 2019

Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis.
Ken Masuda; Yutaka Fujiwara; Yuki Shinno; Takaaki Mizuno; Jun Sato; Ryo Morita; Yuji Matsumoto; Shuji Murakami; Yasushi Goto; Shintaro Kanda; Hidehito Horinouchi; Noboru Yamamoto; Yuichiro Ohe
Journal of thoracic disease, Jul. 2019

Lung Cancer with a Small Cell Carcinoma Component Diagnosed from Pleural Effusion and a Squamous Cell Carcinoma Component Diagnosed from the Tumor.
Yoshiaki Zaizen; Takaaki Tokito; Ken Masuda; Koichi Azuma; Yoshiki Naito; Shingo Tsuneyoshi; Yuki Sakazaki; Norikazu Matsuo; Hidenobu Ishii; Kazuhiko Yamada; Jun Akiba; Tomoaki Hoshino
Internal medicine (Tokyo, Japan), 01 Dec. 2018

Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
Ken Masuda; Takaaki Tokito; Koichi Azuma; Eriko Yanagida; Masayuki Nakamura; Yoshiko Naito; Norikazu Matsuo; Hidenobu Ishii; Kazuhiko Yamada; Jun Akiba; Tomoaki Hoshino
Thoracic cancer, Jun. 2018

Successful Treatment of Rapidly Progressive Unclassifiable Idiopathic Interstitial Pneumonia with Anti-melanoma Differentiation-associated Gene-5 Antibody by Intensive Immunosuppressive Therapy.
Takuma Koga; Shinjiro Kaieda; Masaki Okamoto; Ken Masuda; Kyoko Fujimoto; Satoshi Sakamoto; Masayuki Nakamura; Masaki Tominaga; Tomotaka Kawayama; Kiminori Fujimoto; Tomoaki Hoshino; Hiroaki Ida
Internal medicine (Tokyo, Japan), 01 Apr. 2018

Dental Technicians' Pneumoconiosis.
Masaki Okamoto; Masaki Tominaga; Shigeki Shimizu; Chiyo Yano; Ken Masuda; Masayuki Nakamura; Yoshiaki Zaizen; Takashi Nouno; Satoshi Sakamoto; Mitsuru Yokoyama; Tomotaka Kawayama; Tomoaki Hoshino
Internal medicine (Tokyo, Japan), 15 Dec. 2017